| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1,344.5 | 1,209.3 |
| Gross profit | 864.4 | 731.4 |
| Profit before tax | 334.7 | 352.3 |
| Net income | 275.1 | 283.8 |
| EPS (diluted, $ a share) | $0.72 | $0.70 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -3.1% |
|---|---|
| Revenue, year on year | +11.2% |
| Gross margin | 64.3% |
| Operating margin | 24.3% |
10-Q filed with the SEC, NASDAQ: DXCM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Dexcom Inc: key numbers
- Share price
- $81.61Close, Nov 16
- Market cap
- $30.4B
- Shares outstanding
- 372.95MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Dexcom Inc
All →DexCom Earnings Call: Key Takeaways
Dexcom delivered 11% revenue growth and record new patient starts, raising full-year guidance while navigating a minor PBM contract loss and preparing for a landmark CMS coverage expansion for non-insulin type 2 patients.
- Call
- Oct 29, 2026, 4:30 PM ET
Dexcom Financial Results
Dexcom reported Q3 2026 revenue of $1.34 billion, representing 11% year-over-year growth, and raised its full-year 2026 revenue guidance to $5.20-$5.25 billion. Alongside the results, the company announced that its Board of Directors authorized a new $1.0 billion share repurchase program effective through December 31, 2027.
“This quarter, we continued to build momentum across the business, delivering strong revenue growth and margin progression, strengthening our clinical evidence, and advancing key product and operational initiatives. This performance enabled us to again raise our full-year revenue and operating margin guidance and reinforces our confidence in our ability to deliver on the long-term objectives we outlined at Investor Day.”
Jake Leach, Dexcom’s president and CEO
Dexcom EVP Chief People & Culture Off Sadie Stern Sells $202K of Stock
Sadie Stern, EVP Chief People & Culture Off, sold 2,565 shares of Dexcom Inc at $78.62 a share, worth $202K in total on Oct 27, 2026. Shares held after the trade: 120,913 (-2.1%).
- Value
- $202K
- Shares
- 2,565
- Price
- $78.62
- Role
- EVP Chief People & Culture Off
- Holding change
- -2.1%
- Trade date
- Oct 27, 2026
Dexcom EVP Chief Legal Compliance Off Michael Jon Brown Sells $145K of Stock
Michael Jon Brown, EVP Chief Legal Compliance Off, sold 1,700 shares of Dexcom Inc at $85.48 a share, worth $145K in total on Oct 15, 2026. Shares held after the trade: 98,185 (-1.7%).
- Value
- $145K
- Shares
- 1,700
- Price
- $85.48
- Role
- EVP Chief Legal Compliance Off
- Holding change
- -1.7%
- Trade date
- Oct 15, 2026
Dexcom EVP Chief People & Culture Off Sadie Stern Sells $221K of Stock
Sadie Stern, EVP Chief People & Culture Off, sold 2,565 shares of Dexcom Inc at $86.15 a share, worth $221K in total on Sep 28, 2026. Shares held after the trade: 123,478 (-2.0%).
- Value
- $221K
- Shares
- 2,565
- Price
- $86.15
- Role
- EVP Chief People & Culture Off
- Holding change
- -2.0%
- Trade date
- Sep 28, 2026
Dexcom Insider Nicholas Augustinos Sells $680K of Stock
Nicholas Augustinos sold 8,089 shares of Dexcom Inc at $84.02 to $84.04 a share (average $84.04) in 2 transactions, worth $680K in total between Sep 14, 2026 and Sep 15, 2026. Shares held after the trade: 29,293 (-18.2%).
- Value
- $680K
- Shares
- 8,089
- Average price
- $84.04
- Holding change
- -18.2%
- Trade date
- Sep 14, 2026 to Sep 15, 2026